September 18th 2024
Your daily dose of the clinical news you may have missed.
September 17th 2024
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
September 13th 2024
Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.
Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.
September 12th 2024
Daily Dose: DAPT Should Remain Gold Standard for Percutaneous Coronary Intervention
Your daily dose of clinical news you may have missed.
The Worst States for Health Care in the US: 2023
Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.
Increased Step Count Tied to Better Health for Patients with Heart Failure
New research shows that patients with heart failure who had more steps per day and increasing steps per day experienced better health status over 12 weeks.
Daily Dose: Semaglutide 2.4 mg Benefits Patients with Heart Failure and Obesity
Daily Dose: Aspirin for Secondary Prevention of Cardiovascular Disease
Dual Antiplatelet Therapy Should Remain Gold Standard for Percutaneous Coronary Intervention, Say Authors of New Study
ESC 2023: New data showed an aspirin-free strategy after PCI did not reduce major bleeding event risk vs DAPT, while omission of aspirin proved noninferior for CV events in high-risk patients.
Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations
The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
Dapagliflozin Did Not Meet Primary Endpoint in DICTATE-AHF Trial of Patients with Acute Decompensated Heart Failure
ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.
Daily Dose: Semaglutide May Benefit 93 Million US Adults
A daily dose of clinical news on Patient Care you may have missed.
Frail Elderly at High Risk of Bleeding Following VKA-DOAC Switch: Surprise Outcome Shared at ESC Congress
Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.
Semaglutide 2.4 mg Significantly Reduces HF Symptom Burden, Body Weight in Adults with HFpEF and Obesity
ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.
Cardiorenal Risk Estimates in T2D Mediated by Common Biomarker Response to Canagliflozin
Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
Aspirin Underused for Secondary Prevention of CVD Worldwide, Especially in Lower-Income Countries
In an analysis of participant data from health surveys, less than half of eligible persons in the overall pooled sample were taking aspirin for secondary prevention of CVD.
Obesity Management in Primary Care: Tailor Nutrition Plans to Individual Patient Needs
Before creating a nutrition plan for patients with obesity, clinicians should first understand their eating patterns, says one obesity expert.
Daily Dose: Recreational Drug Use in Patients with Acute CV Events
Semaglutide 2.4 mg Could Reduce US Obesity by Half, Prevent 1.5 million CVD Events
More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.
Patients with COVID-19 More Likely to Develop Hypertension than Those with Influenza, Shows New Study
Patients hospitalized with COVID-19 were 2-times more likely to develop persistent hypertension than their influenza counterparts, according to results.
Recreational Drug Use Linked to 9-Fold Higher Rate of Adverse Outcomes in Intensive Cardiac Care
Various illicit substances were detected in urine assays of 1 in 10 patients admitted to cardiac intensive care, according to findings of new French study.
For Patients with Obesity, Expert Discusses Importance of Checking Current Medications before Prescribing New Therapies
Dr Alina Elperin details which medications primary care clinicians should be prepared to prescribe patients with obesity to help prevent cardiovascular disease, here.
Social Determinants of Health Drive CVD Mortality Differences Between Black and White Adults
Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.
Daily Dose: Effects of Cuff Size on Accuracy of BP Readings
Sotagliflozin Cut Risk by >50% for HF Rehospitalization and CV Death when Started Before Discharge
A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.
Daily Dose: Late Start for Statins Still a Win?
Expert Details the Top 3 CV Complications Seen in Patients with Obesity
Internist and obesity medicine specialist Alina Elperin, MD, details the most common cardiovascular complications that she has observed in patients with obesity.
Antiobesity Medication Semaglutide 2.4 mg Reduced Risk of MACE by 20%: Topline Results from Landmark SELECT Trial
The reduction in risk of CV events, the first to be shown by an antiobesity drug, was higher than expected and could help alter perceptions of the agents as "lifestyle drugs."
For Accurate BP Measurement, Cuff Size Must Be "Just Right"
Blood pressure cuffs that are too large or too small for an individual's upper arm return measurements that may misguide therapeutic decisions, say study authors.
Screen Patients with Obesity for These 2 CVD Risk Factors, Says One Expert
Obesity medicine specialist and internist Alina Elperin, MD, shares why screening for obstructive sleep apnea and metabolic disease in patients with obesity is crucial.
Daily Dose: Regular Alcohol Intake Raises Risk of High Blood Pressure
7 New Approved Drugs for Primary Care: Q2 2023
The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?